This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message Sent On: Sat Oct 30 13:18:20 2021 Search: nor-NOHA 20 selected items PubMed Results Items 1-20 of 20 (Display the 20 citations in PubMed) 1: Crompton RA, Williams H, Campbell L, Lim HK, Saville C, Ansell DM, Reid A, Wong J, Vardy LA, Hardman MJ, Cruickshank SM. An epidermal-specific role for arginase1 during cutaneous wound repair. J Invest Dermatol. 2021 Oct 25:S0022-202X(21)02288-0. doi: 10.1016/j.jid.2021.09.009. Epub ahead of print. PMID: 34710388. 2: Wang H, Ji J, Zhuang Y, Zhou X, Zhao Y, Zhang X. PMA induces the differentiation of monocytes into immunosuppressive MDSCs. Clin Exp Immunol. 2021 Nov;206(2):216-225. doi: 10.1111/cei.13657. Epub 2021 Sep 9. PMID: 34453319; PMCID: PMC8506123. 3: Mittal A, Wang M, Vidyarthi A, Yanez D, Pizzurro G, Thakral D, Tracy E, Colegio OR. Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma. Sci Rep. 2021 May 24;11(1):10731. doi: 10.1038/s41598-021-90200-y. PMID: 34031449; PMCID: PMC8144401. 4: André C, Guillaume YC. Development of a new nano arginase HPLC capillary column for the fast screening of arginase inhibitors and evaluation of their binding affinity. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 15;1175:122751. doi: 10.1016/j.jchromb.2021.122751. Epub 2021 May 1. PMID: 33991957. 5: Scholle MD, Gurard-Levin ZA. Development of a Novel Label-Free and High- Throughput Arginase-1 Assay Using Self-Assembled Monolayer Desorption Ionization Mass Spectrometry. SLAS Discov. 2021 Jul;26(6):775-782. doi: 10.1177/24725552211000677. Epub 2021 Mar 23. PMID: 33754845. 6: Hara M, Torisu K, Tomita K, Kawai Y, Tsuruya K, Nakano T, Kitazono T. Arginase 2 is a mediator of ischemia-reperfusion injury in the kidney through regulation of nitrosative stress. Kidney Int. 2020 Sep;98(3):673-685. doi: 10.1016/j.kint.2020.03.032. Epub 2020 Apr 25. PMID: 32739205. 7: Grobben Y, Uitdehaag JCM, Willemsen-Seegers N, Tabak WWA, de Man J, Buijsman RC, Zaman GJR. Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. J Struct Biol X. 2019 Nov 26;4:100014. doi: 10.1016/j.yjsbx.2019.100014. PMID: 32647818; PMCID: PMC7337048. 8: Azambuja JH, Ludwig N, Yerneni SS, Braganhol E, Whiteside TL. Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression. Int J Mol Sci. 2020 Jun 2;21(11):3990. doi: 10.3390/ijms21113990. PMID: 32498400; PMCID: PMC7312363. 9: Hein TW, Omae T, Xu W, Yoshida A, Kuo L. Role of Arginase in Selective Impairment of Endothelium-Dependent Nitric Oxide Synthase-Mediated Dilation of Retinal Arterioles during Early Diabetes. Invest Ophthalmol Vis Sci. 2020 May 11;61(5):36. doi: 10.1167/iovs.61.5.36. PMID: 32437549; PMCID: PMC7405695. 10: Hannemann J, Roskam TI, Eilermann I, Siques P, Brito J, Böger R. Pre- Analytical and Clinical Validation of a Dried Blood Spot Assay for Asymmetric Dimethylarginine and L-Arginine. J Clin Med. 2020 Apr 9;9(4):1072. doi: 10.3390/jcm9041072. PMID: 32283799; PMCID: PMC7230730. 11: Momma TY, Ottaviani JI. Arginase inhibitor, Nω-hydroxy-L- norarginine, spontaneously releases biologically active NO-like molecule: Limitations for research applications. Free Radic Biol Med. 2020 May 20;152:74-82. doi: 10.1016/j.freeradbiomed.2020.02.033. Epub 2020 Mar 1. PMID: 32131024. 12: Muessig JM, Moellhoff L, Noelle J, Kaya S, Hidalgo Pareja L, Masyuk M, Roden M, Kelm M, Jung C. Poor glycemic control impairs the cardioprotective effects of red blood cells on myocardial ischemia/reperfusion injury. Nitric Oxide. 2020 Apr 1;97:1-10. doi: 10.1016/j.niox.2020.01.008. Epub 2020 Jan 22. PMID: 31981741. 13: Bujor A, Miron A, Luca SV, Skalicka-Wozniak K, Silion M, Trifan A, Girard C, Demougeot C, Totoson P. Vasorelaxant effects of Crataegus pentagyna: Links with arginase inhibition and phenolic profile. J Ethnopharmacol. 2020 Apr 24;252:112559. doi: 10.1016/j.jep.2020.112559. Epub 2020 Jan 11. Erratum in: J Ethnopharmacol. 2021 Jun 12;273:113962. PMID: 31935497. 14: Nahidi S, Gholami E, Taslimi Y, Habibzadeh S, Seyed N, Davarpanah E, Ghanadan A, Rafati S, Taheri T. The outcome of arginase activity inhibition in BALB/c mice hosting Leishmania tropica. Parasite Immunol. 2020 Mar;42(3):e12691. doi: 10.1111/pim.12691. Epub 2020 Jan 7. PMID: 31811772. 15: Avtandilyan N, Javrushyan H, Mamikonyan A, Grigoryan A, Trchounian A. The potential therapeutic effect of NG-hydroxy-nor-L-arginine in 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats. Exp Mol Pathol. 2019 Dec;111:104316. doi: 10.1016/j.yexmp.2019.104316. Epub 2019 Oct 17. PMID: 31629728. 16: Van Zandt MC, Jagdmann GE, Whitehouse DL, Ji M, Savoy J, Potapova O, Cousido-Siah A, Mitschler A, Howard EI, Pyle AM, Podjarny AD. Discovery of N-Substituted 3-Amino-4-(3-boronopropyl)pyrrolidine-3-carboxylic Acids as Highly Potent Third-Generation Inhibitors of Human Arginase I and II. J Med Chem. 2019 Sep 12;62(17):8164-8177. doi: 10.1021/acs.jmedchem.9b00931. Epub 2019 Aug 23. PMID: 31408339. 17: Hein TW, Xu X, Ren Y, Xu W, Tsai SH, Thengchaisri N, Kuo L. Requisite roles of LOX-1, JNK, and arginase in diabetes-induced endothelial vasodilator dysfunction of porcine coronary arterioles. J Mol Cell Cardiol. 2019 Jun;131:82-90. doi: 10.1016/j.yjmcc.2019.04.015. Epub 2019 Apr 20. PMID: 31015037; PMCID: PMC6911365. 18: Bordy R, Quirié A, Marie C, Wendling D, Totoson P, Demougeot C. Vascular Arginase Is a Relevant Target to Improve Cerebrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Evidence from the Model of Adjuvant-Induced Arthritis. Transl Stroke Res. 2020 Feb;11(1):4-15. doi: 10.1007/s12975-019-00699-7. Epub 2019 Mar 18. PMID: 30887278. 19: Ding LY, Wang YF, Shen YZ, Zhou G, Zhang X, Wang MZ, Loor JJ, Zhang J. Effects of arginase inhibition via jugular infusion of Nω-hydroxy- nor-l-arginine on metabolic and immune indices in lactating dairy cows. J Dairy Sci. 2019 Apr;102(4):3310-3320. doi: 10.3168/jds.2018-14879. Epub 2019 Feb 7. PMID: 30738683. 20: Meade RD, Fujii N, McGarr GW, Alexander LM, Boulay P, Sigal RJ, Kenny GP. Local arginase inhibition does not modulate cutaneous vasodilation or sweating in young and older men during exercise. J Appl Physiol (1985). 2019 Apr 1;126(4):1129-1137. doi: 10.1152/japplphysiol.00657.2018. Epub 2019 Jan 17. PMID: 30653418; PMCID: PMC6485684.

C5H14CL2N4O3

249.092

0

C, 24.11; H, 5.67; Cl, 28.46; N, 22.49; O, 19.27

291758-32-2

189302-40-7;1140844-63-8 (acetate);291758-32-2 (HCl);

O=C(O)[C@@H](N)CCN/C(N)=N/O.[H]Cl.[H]Cl

AKPIIXWPTMFQQJ-QTNFYWBSSA-N

InChI=1S/C5H12N4O3.2ClH/c6-3(4(10)11)1-2-8-5(7)9-12;;/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9);2*1H/t3-;;/m0../s1

(S,E)-2-amino-4-(2-hydroxyguanidino)butanoic acid dihydrochloride

N-Hydroxy-nor-L-Arginine; H-norArg(delta-OH)-OH; nor-NOHA HCl; nor-NOHA hydrochloride.

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)